Iniciar sesión
Registrarse
Restablecer contraseña
Publicar y Distribuir
Soluciones de Publicación
Soluciones de Distribución
Temas
Arquitectura y diseño
Artes
Ciencias Sociales
Ciencias de la Información y Bibliotecas, Estudios del Libro
Ciencias de la vida
Ciencias de los materiales
Deporte y tiempo libre
Estudios clásicos y del Cercano Oriente antiguo
Estudios culturales
Estudios judíos
Farmacia
Filosofía
Física
Geociencias
Historia
Informática
Ingeniería
Interés general
Ley
Lingüística y semiótica
Literatura
Matemáticas
Medicina
Música
Negocios y Economía
Química
Química industrial
Teología y religión
Publicaciones
Revistas
Libros
Actas
Editoriales
Blog
Contacto
Buscar
EUR
USD
GBP
Español
English
Deutsch
Polski
Español
Français
Italiano
Carrito
Home
Revistas
Asian Biomedicine
Volumen 18 (2024): Edición 2 (April 2024)
Acceso abierto
Treatment of cholangiocarcinoma by pGCsiRNA-vascular endothelial growth factor in vivo
Shenglin Lu
Shenglin Lu
y
Jun Li
Jun Li
| 30 abr 2024
Asian Biomedicine
Volumen 18 (2024): Edición 2 (April 2024)
Acerca de este artículo
Artículo anterior
Artículo siguiente
Resumen
Artículo
Figuras y tablas
Referencias
Autores
Artículos en este número
Vista previa
PDF
Cite
Compartir
Article Category:
Original article
Publicado en línea:
30 abr 2024
Páginas:
61 - 68
DOI:
https://doi.org/10.2478/abm-2024-0009
Palabras clave
cholangiocarcinoma
,
matrix metalloproteinase
,
mouse
,
treatment
,
vascular endothelial growth factor
© 2024 Shenglin Lu et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Figure 1.
Sequencing results of pGCsiRNA-VEGF containing U6 promoter. The results showed that 6.3 kb linearized vectors and 63 bp oligonucleotide fragments were obtained. pGCsiRNA, VEGF, vascular endothelial growth factor.
Figure 2.
Tumor growth curves. The tumor volume was smaller in the pGCsiRNA-VEGF group than that in the mock group and the si-scramble group on Day 27 of treatment. VEGF, vascular endothelial growth factor.
Figure 3.
Tumor weights. On Day 28 of treatment, the tumor weight was smaller in the pGCsiRNA-VEGF group than that in the mock group and the si-scramble group. VEGF, vascular endothelial growth factor.
Figure 4.
Tumor volumes. Tumor growth was inhibited in nude mice. VEGF, vascular endothelial growth factor.
Figure 5.
Protein expressions of VEGF, MMP2 and MMP9. The protein expressions of VEGF, MMP2, and MMP9 declined in pGCsiRNA-VEGF group compared with those in the mock and si-scramble groups. MMP, matrix metalloproteinase; VEGF, vascular endothelial growth factor.
Figure 6.
Changes in mRNA expressions of VEGF, MMP2, and MMP9 in tumor tissues. The mRNA expressions of VEGF, MMP2, and MMP9 were significantly lower in the pGCsiRNA-VEGF group than those in the mock group and the si-scramble group. MMP, matrix metalloproteinase; VEGF, vascular endothelial growth factor.
Figure 7.
Morphological changes of tumor tissues. There was obvious apoptosis of tumor tissues, a large number of cells died, the tissue structures mostly disappeared, karyopyknosis was found, a large number of apoptotic cells were dispersed around the tissues, and the cells lost their normal morphology in pGCsiRNA-VEGF group compared to those in the mock and si-scramble groups. VEGF, vascular endothelial growth factor.
Figure 8.
VEGF expressions of the different groups. The protein expression of VEGF was significantly suppressed in the pGCsiRNA-VEGF group compared with that in the mock group and the si-scramble group. VEGF, vascular endothelial growth factor.